Literature DB >> 26137132

Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis.

Yi-Fu He1, Hui-Qin Luo2, Wei Wang2, Jian Chen2, Yi-Wei Yao2, Shan-Bao Cai3, Jie He4, Ying Yan5, Shu-Sheng Wu5, Xiao-Xiu Hu5, Li-Hong Ke5, Jia-Yu Niu5, Hui-Min Li5, Chu-Shu Ji2, Bing Hu2.   

Abstract

The present study aimed to analyze the clinical characteristics and prognosis-related factors of non-small cell lung cancer (NSCLC) patients with bone metastases at the time of diagnosis. A total of 46 NSCLC patients with skeletal metastases at the time of diagnosis from Anhui Provincial Hospital and Anhui Provincial Cancer Hospital Affiliated to Anhui Medical University (Hefei, China) between February 2010 and February 2012 were investigated retrospectively. The median age was 58 years, with a range of 40-80 years, the ratio of males and females was 2:1, and adenocarcinoma and squamous cell carcinoma accounted for 71.7 and 28.3% of cases, respectively. Furthermore, 84.8% of patients exhibited multiple skeletal metastases at more than two sites and 54.3% of patients experienced skeletal-related events at the time of diagnosis. The median overall survival (OS) time of the patients was 237 days, and Kaplan-Meier analysis demonstrated that patients with adenocarcinoma (P=0.002), single bone metastases (P=0.023), an Eastern Cooperative Oncology Group performance status of 0-1 (P<0.001) or positive expression of estrogen receptor (ER)-β (P=0.039) exhibited significantly longer survival times. Furthermore, multivariate analysis identified the following independent predictors of OS: Tumor subtype (P=0.022), the number of bone metastases (P=0.016) and an ER-β-positive tumor (P=0.035). In the cohort of NSCLC patients with bone metastases at the time of diagnosis, adenocarcinoma and multiple skeletal metastases were most common.

Entities:  

Keywords:  bone metastases; clinical characteristics; estrogen receptor-β; non-small cell lung cancer; prognostic factors

Year:  2015        PMID: 26137132      PMCID: PMC4473594          DOI: 10.3892/ol.2015.3081

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

Review 1.  Estrogen receptor beta in cancer: an attractive target for therapy.

Authors:  Daniela Gallo; Ilaria De Stefano; Maria Grazia Prisco; Giovanni Scambia; Gabriella Ferrandina
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

Authors:  Laura P Stabile; Jennifer S Lyker; Christopher T Gubish; Weiping Zhang; Jennifer R Grandis; Jill M Siegfried
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

3.  Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex.

Authors:  Ann G Schwartz; Geoffrey M Prysak; Valerie Murphy; Fulvio Lonardo; Harvey Pass; Jan Schwartz; Sam Brooks
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

4.  Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hormonal status in lung adenocarcinoma.

Authors:  Vianey Rodriguez-Lara; Erika Peña-Mirabal; Renata Baez-Saldaña; Ana Luisa Esparza-Silva; Eduardo García-Zepeda; Marco Antonio Cerbon Cervantes; Daniel Diaz; Teresa Imelda Fortoul
Journal:  Arch Med Res       Date:  2014-01-28       Impact factor: 2.235

5.  Prognostic factors in patients with inoperable non-small cell lung cancer--an analysis of long-term survival patients.

Authors:  Rina Ohashi; Kazuhisa Takahashi; Kayo Miura; Toshiji Ishiwata; Shouko Sakuraba; Yoshinosuke Fukuchi
Journal:  Gan To Kagaku Ryoho       Date:  2006-11

6.  Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells.

Authors:  Xi-Ying Wang; Yan Wang; Hong-Chun Liu
Journal:  Biomed Pharmacother       Date:  2011-08-25       Impact factor: 6.529

7.  Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.

Authors:  Hyun-Mi Bae; Se-Hoon Lee; Tae Min Kim; Dong-Wan Kim; Seok-Chul Yang; Hong Gyun Wu; Young Whan Kim; Dae Seog Heo
Journal:  Lung Cancer       Date:  2012-06-04       Impact factor: 5.705

8.  Annual report on status of cancer in China, 2010.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

9.  Adenosquamous carcinoma of the lung: CT, FDG PET, and clinicopathologic findings.

Authors:  Youkyung Lee; Jin-Haeng Chung; Sang Eun Kim; Tae Jung Kim; Kyung Won Lee
Journal:  Clin Nucl Med       Date:  2014-02       Impact factor: 7.794

10.  The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma.

Authors:  Paweł Krawczyk; Marcin Nicoś; Rodryg Ramlau; Tomasz Powrózek; Kamila Wojas-Krawczyk; Sylwia Sura; Bożena Jarosz; Justyna Szumiło; Edward Warda; Tomasz Mazurkiewicz; Marek Sawicki; Janusz Milanowski
Journal:  Pathol Oncol Res       Date:  2013-07-14       Impact factor: 3.201

View more
  7 in total

1.  Prognostic factors in patients with skeletal-related events at non-small-cell lung cancer diagnosis.

Authors:  Hiroyuki Tominaga; Takao Setoguchi; Hirofumi Shimada; Satoshi Nagano; Hiromi Sasaki; Yasuhiro Ishidou; Masami Sato; Keiko Mizuno; Hiromasa Inoue; Setsuro Komiya
Journal:  Mol Clin Oncol       Date:  2017-08-25

2.  Upregulation of estrogen receptor beta protein but not mRNA predicts poor prognosis and may be associated with enhanced translation in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Wangyang Meng; Yongde Liao; Jiaping Chen; Yangwei Wang; Yunchong Meng; Kuo Li; Han Xiao
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

3.  Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States.

Authors:  Brian De; Ryan Rhome; Vikram Jairam; Umut Özbek; Randall F Holcombe; Michael Buckstein; Celina Ang
Journal:  Gastric Cancer       Date:  2018-04-24       Impact factor: 7.370

4.  Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.

Authors:  Adam W Nelson; Arnoud J Groen; Jodi L Miller; Anne Y Warren; Kelly A Holmes; Gerard A Tarulli; Wayne D Tilley; Benita S Katzenellenbogen; John R Hawse; Vincent J Gnanapragasam; Jason S Carroll
Journal:  Mol Cell Endocrinol       Date:  2016-11-23       Impact factor: 4.102

5.  The pattern of bone involvement, management, and outcomes in patients with nonsmall cell lung cancer: A retrospective study.

Authors:  Abdulrahman M Jazieh; Thuraya S AlSumai; Yosra Z Ali; Nagham R Sheblaq; Mohammad Alkaiyat
Journal:  Ann Thorac Med       Date:  2018 Jul-Sep       Impact factor: 2.219

6.  Lagerstroemia speciosa (L.) Pers Leaf Extract Attenuates Lung Tumorigenesis via Alleviating Oxidative Stress, Inflammation and Apoptosis.

Authors:  Amria M Mousa; Nermin M El-Sammad; Abeer H Abdel-Halim; Nayera Anwar; Wagdy K B Khalil; Mahmoud Nawwar; Amani N Hashim; Elsayed A Elsayed; Sherien K Hassan
Journal:  Biomolecules       Date:  2019-12-12

7.  Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.

Authors:  Xu Guo; Wenjuan Ma; Haixiao Wu; Yao Xu; Dezheng Wang; Shuang Zhang; Zheng Liu; Vladimir P Chekhonin; Karl Peltzer; Jin Zhang; Xin Wang; Chao Zhang
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.